Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome
Gerald F. Watts(Royal Perth Hospital), Anthony G. Johnson(GlaxoSmithKline (Australia)), F. Loehrer(GlaxoSmithKline (Australia)), Dick C. Chan(The University of Western Australia), Kevin D. Croft(University of Western Australia), Juying Ji(The University of Western Australia), P. Hugh R. Barrett(The University of Western Australia), Adrian Serone(GlaxoSmithKline (Australia))
Cited by 218
Related Papers
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k